Authors
Latest:
Cell Therapy May Yield Deep Remissions in Multiple MyelomaIde-cel's March 2021 FDA approval marks a significant advance in relapsed/refractory multiple myeloma treatment.
Latest:
Making Antigen-Presenting Cells With Cell Squeeze TechnologyThe founder and chief executive officer of SQZ Biotech discussed the potential of their APC platform to treat a variety of tumors.
Latest:
Arnaud Lacoste, PhD, on AURN001‘s Immunomodulatory PropertiesThe chief scientific officer of Aurion Biotech discussed the properties of the cell therapy for corneal dystrophies, which was recently approved in Japan.
Latest:
Gene and Cell Therapy Approaches Hold Promise for Usher SyndromeIn honor of Usher Syndrome Awareness Day, CGTLive® interviewed Zheng-Yi Chen, DPhil, associate professor, Otolaryngology–Head and Neck Surgery, Harvard Medical School, about the current state of research in this rare disease.
Latest:
HSCT With Omidubicel Achieved Robust Immune Reconstitution and Lower Rates of Severe Infection Compared to UCB TransplantationExpert hematologist/oncologist Paul Szabolcs, MD, reviews positive data from a clinical trial comparing hematopoietic stem cell transplantation and omidubicel with standard cord blood transplantation.
Latest:
Aude Chapuis, MD, on Improving TCR T-Cell Therapies for Cancer TreatmentThe associate professor in the Translational Science and Therapeutics Division at Fred Hutch Cancer Center discussed her lab’s research on making TCR T-cell therapies more effective.
Latest:
Kyle Garland, PhD, on the Potential of mRNA-engineered iPSC-derived Cell Therapies for Solid TumorsThe senior scientist at Eterna Therapeutics discussed the company’s numerous presentations at ASGCT’s 2023 conference.
Latest:
Barry J Byrne, MD, PhD, on Making Decisions in the Face of Rapidly Expanding Treatment OptionsThe chief medical advisor of Muscular Dystrophy Association (MDA) gave his view on treatment decision-making in the world of new options for DMD.
Latest:
Reducing Off-Target Effects of CAR T-Cell TherapiesEric von Hofe, PhD, president and chief operating officer of AffyImmune, discussed advantages of the Affinity tuning platform.
Latest:
Barry Paul, MD, on Managing CRS and ICANS in Patients Receiving CAR-T for CancerPaul discussed common symptoms and typical treatments for the 2 adverse events.
Latest:
Alice Zhou, MD, PhD, and Omar Butt, MD, PhD, on Surprising Associations With Neurotoxicity and Neurofilament LightThe medical oncologists at Washington University School of Medicine in St. Louis discussed surprising findings from their retrospective study.
Latest:
New Research Identifies Safe Harbors for Gene Editing TherapiesThe Genomics and Epigenetic Guided Safe Harbor mapper will aid in the future design of gene-editing therapies.
Latest:
Gene Therapy for Rare Diseases: Latest UpdatesKinnari Patel, PharmD, president and chief operating officer of Rocket Pharmaceuticals, discussed Rocket Pharma’s programs.
Latest:
Brian Shaffer, MD, on Promising Signs of Efficacy in Post-CAR-T NHL NK Cell TherapyThe assistant attending physician and bone marrow transplant specialist at Memorial Sloan Kettering Cancer Center discussed updated data on GDA-201 plus rituximab.
Latest:
Evaluating Allogeneic CAR-T P-BCMA-ALLO1 in R/R Multiple MyelomaBhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center, discussed interim data from the phase 1/1b clinical trial evaluating Poseida's CAR-T.
Latest:
Nicole Paulk, PhD, on Applying AAV Approaches in OncologyThe CEO, founder, and president of Siren Biotechnology discussed the preclinical data she presented at ASGCT’s 2023 meeting on the use of AAV immuno-gene therapy for high-grade gliomas.
Latest:
Joseph Fraietta, PhD, on Achieving a Deeper Understanding of CAR T-Cell TherapyThe assistant professor of microbiology at Penn Medicine discussed further research to be done with EGR2 and type 1 interferon.
Latest:
Oncolytic Viruses are a Novel Delivery System in Malignant TumorsGenetically modified oncolytic viruses may provide a new strategy against malignant tumors.
Latest:
Holly Peay, PhD, on Patient Preference Research as a Means of Patient ExpressionThe senior research scientist at RTI International discussed how patient preference studies can help patients with rare diseases have their voices heard.
Latest:
Integrating TIL-Based Therapy into Melanoma Treatment: Omar Hamid, MDThe chief of translational Research and immunotherapy at The Angeles Clinic and Research Institute discussed the integration of tumor infiltrating lymphocyte–based therapy into the melanoma armamentarium.
Latest:
Geoffrey Hodge on Developing CAR T-Cell Therapies for Solid TumorsGeoffrey Hodge, chief executive officer of SOTIO Biotech US, discussed the company's development of the BOXR cell therapy platform.
Latest:
Xaviar Michael Jones, MD, on Expanding Horizons in RNA Therapeutics Through CollaborationThe postdoctoral research fellow at Cedars Sinai Medical Center discussed the future of RNA therapy in the context of research in systemic sclerosis he presented at AHA’s Scientific Sessions 2023.
Latest:
Benjamin L. Schlechter, MD, on TAC01-HER2 in HER2-Positive Solid TumorsSchlechter discussed the potential advantages of TAC01-HER2 over current standards of care.
Latest:
A Review of Autologous Stem Cell Transplantation in AmyloidosisIuliana Vaxman, MD, and Angela Dispenzieri, MD, review eligibility criteria for ASCT in AL amyloidosis, conditioning dosing, efficacy in terms of hematologic and organ response, and future areas of research.
Latest:
Michel Michaelides, MD, FACP, on Gene Therapy's Potential in Retinitis PigmentosaThe professor of ophthalmology at the University College London Institute of Ophthalmology discussed the likely rise of gene therapies in inherited retinal diseases.
Latest:
ACGT's Highlights From the International Oncolytic Virotherapy ConferenceTake a look back at the 2023 conference, hosted by the University of Calgary and McMaster University, and held in Banff, Alberta, Canada.
Latest:
Andras Heczey, MD, on Antitumor Activity of CAR NKTs in Solid TumorsThe director of the Liver Tumor Program at Texas Children’s Hospital discussed a phase 1 study of CAR NK T-cells in neuroblastoma.
Latest:
Cilta-cel Garners More Positive Data in Early and Late Relapsed Multiple Myeloma TreatmentYing Huang, chief executive officer, Legend Biotech, discussed new data from the CARTIFAN-1 and CARTITUDE-2 studies.
Latest:
David Rawlings, MD, on the Potential of Engineered Treg Cells to Treat Autoimmune DiseasesThe director of the Center for Immunity and Immunotherapies at Seattle Children's Research Institute discussed preclinical research on overcoming limitations of Treg cells through genetic engineering.
Latest:
Samer Srour, MB ChB, MS, on Improving CAR T-Cell Therapy for Solid TumorsThe assistant professor of stem cell transplantation at MD Anderson Cancer Center discussed positive data in ccRCC that he believes should excite the solid tumor field as a whole.
